In conclusion, according to some preclinical data pharmacological inhibition of TDO2 and IDO1 might represent a safe and efficient approach to treat cancer by promoting tumoral destruction by the immune system, and consequently potentiating cancer immunotherapies whether it is a single shot inhibition or a two-shot inhibition (IDO1 and TDO2). The gene discussed is IDO1; the disease is cancer.